Like clues to a crime, specific molecules in the body can hint at exposure to toxins, infectious agents or even trauma, and so help doctors determine whether and how to treat a patient. In recent years, tiny pieces of RNA called microRNAs have captured scientific attention for their potential as markers of health and disease.
New research at Rockefeller University and Columbia University suggests these small molecules may be able to relay valuable information about damage to the heart: Scientists in Thomas Tuschl’s Laboratory of RNA Molecular Biology have linked an increase in certain microRNAs circulating in the blood with injury to cardiac muscle. The researchers hope that, one day, these molecules might provide the basis for a more sensitive diagnostic tool than those currently available.
“When we profiled the small RNAs circulating in the blood of healthy people versus heart failure patients, we found increases in levels of certain microRNAs expressed by muscle, including three known to originate only in the heart,” says Kemal Akat, the first author and a postdoc in the lab. “Our research suggests these three microRNAs could be used as indicators of injury produced by anything from heart attack to an impact in a car accident.”
The findings were published online July 10 in the Proceedings of the National Academy of Sciences and add to a growing body of knowledge about microRNAs. These small RNA molecules are encoded in the genome, and they fine-tune the expression of genes in the cells that produce them. They also show up in the blood stream, outside the protective environment of the cell. Although microRNAs are present in blood at extremely low levels, the highly sensitive RNA sequencing techniques used by the Rockefeller team can detect them.
Signs of trouble: Postdoc Kemal Akat and colleagues used sensitive RNA sequencing techniques to profile the abundance of microRNAs in samples from healthy people and those suffering from heart failure. They found three RNAs with potential for use as markers of heart injury.
The researchers profiled the microRNA in samples of blood and heart tissue from healthy people and people suffering from one of two types of heart failure, which develops when the heart’s pumping action weakens, making it unable to deliver blood throughout the body.
They compared their microRNA results with those of a protein currently used to diagnose injury to heart muscle: cardiac troponin. This protein occurs within healthy heart muscle cells, but when injured, these cells leak cardiac troponin out into the blood stream, causing its levels to spike in circulation. Something similar appears to happen with microRNAs. The researchers found elevated levels of muscle-associated microRNAs in the blood but not in the heart tissue samples of the heart failure patients.
This similarity, as well as other evidence, suggests microRNAs could also serve as biomarkers for heart injury, and the researchers hope microRNAs could even have an advantage over cardiac troponin. “Cells contain a small pool of soluble cardiac troponin, but the majority is bound to heart muscle filaments. By contrast, the protein complexes that contain microRNA within the cell are fully soluble. For this reason, we suspect microRNAs may be more readily released into circulation and their levels may increase faster than cardiac troponin upon tissue injury,” Akat says.
“RNA sequencing can capture a wide spectrum of microRNAs and other potentially interesting RNA molecules from a tiny sample,” Tuschl says. “This opens the possibility of finding many promising biomarkers like those we found from heart muscle, leading to a more universal test then the current monitoring of single proteins. Some technological barriers must still be overcome before tests based on RNA biomarkers like these can be brought into the clinic, but the potential is there for an entirely new type of clinically important diagnostic tool.”
|Proceedings of the National Academy of Sciences 111, 11151–11156
Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers
Kemal Marc Akat, D’Vesharronne Moore-McGriff, Pavel Morozov, Miguel Brown, Tasos Gogakos, Joel Correa Da Rosa, Aleksandra Mihailovic, Markus Sauer, Ruiping Ji, Aarthi Ramarathnam, Hana Totary-Jain, Zev Williams, Thomas Tuschl and P. Christian Schulze